Propulsid Limited Access Program Allows Off-Label Use To Continue

FDA and Johnson & Johnson are indicating that the new Propulsid limited access program will allow physicians to continue prescribing the drug for more serious conditions than nocturnal heartburn due to gastroesophageal reflux disease, the labeled indication.